These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25664945)

  • 1. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates.
    Solomon JP; Hansel DE
    Adv Anat Pathol; 2015 Mar; 22(2):102-12. PubMed ID: 25664945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder cancer: translating molecular genetic insights into clinical practice.
    Cheng L; Zhang S; MacLennan GT; Williamson SR; Lopez-Beltran A; Montironi R
    Hum Pathol; 2011 Apr; 42(4):455-81. PubMed ID: 21106220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
    Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
    Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder.
    Han Y; Liu Y; Gui Y; Cai Z
    J Surg Oncol; 2013 Feb; 107(2):201-5. PubMed ID: 22766726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic prognostic parameters in bladder urothelial biopsy, transurethral resection, and cystectomy specimens.
    Lapham RL; Grignon D; Ro JY
    Semin Diagn Pathol; 1997 May; 14(2):109-22. PubMed ID: 9179972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histologic grading of urothelial carcinoma: a reappraisal.
    Cheng L; MacLennan GT; Lopez-Beltran A
    Hum Pathol; 2012 Dec; 43(12):2097-108. PubMed ID: 22542126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical study of the proliferating ability and malignant potential of transitional cell carcinoma in the human urinary bladder.
    Yoshikawa H; Ikeuchi T; Kai Y
    Int J Urol; 1996 Jan; 3(1 Suppl):S32-4. PubMed ID: 24304017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and significance of macrophage migration inhibitory factor in bladder urothelial cell carcinoma].
    Guo YS; Dai YP; Li W; Liu LD
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):28-31. PubMed ID: 21575460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series.
    Raspollini MR; Sardi I; Giunti L; Di Lollo S; Baroni G; Stomaci N; Menghetti I; Franchi A
    Hum Pathol; 2011 Aug; 42(8):1149-58. PubMed ID: 21334719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer.
    Minner S; De Silva C; Rink M; Dahlem R; Chun F; Fisch M; Höppner W; Wagner W; Bokemeyer C; Terracciano L; Simon R; Sauter G; Wilczak W
    Pathology; 2012 Aug; 44(5):448-52. PubMed ID: 22772340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
    Zhang Z; Zhang G; Kong C
    Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.
    van der Kwast TH
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
    Fatima N; Osunkoya AO
    Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aquaporin 3 protein expression in transitional cell carcinoma: a potential marker with regard to tumour progression and prognosis?
    Rubenwolf PC; Denzinger S; Otto W
    Eur Urol; 2012 Mar; 61(3):627-8. PubMed ID: 22197473
    [No Abstract]   [Full Text] [Related]  

  • 16. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder.
    Xylinas E; Kluth LA; Lotan Y; Daneshmand S; Rieken M; Karakiewicz PI; Shariat SF
    Urol Oncol; 2014 Apr; 32(3):230-42. PubMed ID: 24332648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive micropapillary urothelial carcinoma of the bladder.
    Lopez-Beltran A; Montironi R; Blanca A; Cheng L
    Hum Pathol; 2010 Aug; 41(8):1159-64. PubMed ID: 20381120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel markers of squamous differentiation in the urinary bladder.
    Huang W; Williamson SR; Rao Q; Lopez-Beltran A; Montironi R; Eble JN; Grignon DJ; Idrees MT; Emerson RE; Zhou XJ; Zhang S; Baldridge LA; Hahn NM; Wang M; Koch MO; Cheng L
    Hum Pathol; 2013 Oct; 44(10):1989-97. PubMed ID: 23806524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer.
    Garg M
    Cancer Metastasis Rev; 2015 Dec; 34(4):691-701. PubMed ID: 26328525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOX4 expression levels in urothelial bladder carcinoma.
    Gunes S; Yegin Z; Sullu Y; Buyukalpelli R; Bagci H
    Pathol Res Pract; 2011 Jul; 207(7):423-7. PubMed ID: 21680105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.